AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03673631 — intervention group
Intervention type: DEVICE
Intervention: NIV
Description: NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
Study NCT03673631 — intervention group
Intervention type: DEVICE
Intervention: NFHC-O2
Description: NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
Study NCT02503111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Hyfrecator ® 2000 Electrosurgical System
Description: Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
Study NCT02503111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation Alone
Description: No treatment to AIN-2 or AIN-3, only active surveillance.
Study NCT00033514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Day 1 4mg/kg IV 2 mg/kg IV weekly.
Study NCT00033514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
Study NCT01028794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
Study NCT01028794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
Study NCT01845337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teysuno
Study NCT03524586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ipsilateral rotation of head
Description: Ipsilateral rotation of head against fixed tube
Study NCT03524586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contralateral rotation of head
Description: Contralateral rotation of head against fixed tube
Study NCT03576456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam 0.5 mg
Description: receive alprazolam prior to angio
Study NCT03576456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: receive placebo prior to angio
Study NCT03312127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILIAC ENDOPROSTHESIS GORE EXCLUDER
Description: Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
Study NCT02073149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose iron as NaFeEDTA
Description: Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
Study NCT02073149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dose iron as ferrous salt
Description: Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
Study NCT02073149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
Study NCT02508493 — intervention group
Intervention type: OTHER
Intervention: Pencil-and-paper Cognitive Tests
Description: Pencil-and-paper versions of the following cognitive tests:~* Digit Symbol Substitution Test (DSST)~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~* Variant of Choice Reaction Time (CRT)~* Variant of the One-back working memory tool
Study NCT01913275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic stenting
Description: Endoscopic stenting to decrease preopertaive jaundice
Study NCT01913275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cholecystojejunostomy
Description: surgical procedure to decrease preoperative jaundice
Study NCT03125460 — intervention group
Intervention type: DEVICE
Intervention: Xpert Bladder Cancer Monitor
Description: in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
Study NCT00391911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
Study NCT00391911 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: N-Acetylcystine and Non CRRT
Description: Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
Study NCT00391911 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo and CRRT
Description: Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
Study NCT00391911 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo and Non CRRT
Description: Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
Study NCT04044625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Description: In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
Study NCT04044625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity NPPV
Description: In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
Study NCT01756209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium 400Mg
Description: magnesium 400 mg + conventional treatment
Study NCT01756209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 10 mg/kg
Description: ibuprofen 10 mg/kg oral single dose
Study NCT01756209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Description: ibuprofen 10 mg/kg oral single dose
Study NCT01756209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen 15 mg/kg
Description: Acetaminophen 15 mg/kg oral single dose
Study NCT01756209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen 15 mg/kg
Description: Acetaminophen 15 mg/kg oral single dose
Study NCT02802527 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Tracheostomy
Study NCT04284579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV cannula
Description: We measure the time duration needed for IV cannulation
Study NCT03225924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: 200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
Study NCT00336960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
Study NCT00336960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Patients receive concurrent fluorouracil IV continuously for 5 weeks.
Study NCT00336960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: 4-10 weeks after completion of chemoradiotherapy
Study NCT00336960 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 days a week for 5 weeks
Study NCT00336960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumor biopsy
Description: at baseline and then at the time of surgical resection
Study NCT00336960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
Study NCT02165735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient activation training
Description: Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
Study NCT02165735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual HIV care
Study NCT00101283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
Study NCT00101283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
Study NCT00101283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
Study NCT02174458 — intervention group
Intervention type: PROCEDURE
Intervention: Body Contouring Surgery
Description: Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
Study NCT02210936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers).
Study NCT03225924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: cycles of 21 days - 375mg/m²
Study NCT03225924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cycles of 21 days - 750 mg/m²
Study NCT03225924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: cycles of 21 days - 50mg/m²
Study NCT03225924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: cycles of 21 days - 1.4mg/m²
Study NCT03225924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: cycles of 21 days - 40mg/m²
Study NCT00082381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide (AC2993)
Description: subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
Study NCT00082381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: subcutaneous injection, once daily; forced titration to target blood glucose level
Study NCT04129385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 20 degree Trendelenburg position
Description: The patients in the intervention group will be placed in trendelenburg position postoperatively.
Study NCT02505360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3
Study NCT00556270 — intervention group
Intervention type: DRUG
Intervention: Matrifen
Description: as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
Study NCT01009866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MR1-1
Description: Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
Study NCT01093066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimal TURB
Description: The TURB will always try to be optically complete.
Study NCT00249613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women-Only
Description: Gender-responsive treatment for women only
Study NCT02345330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.
Study NCT02345330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
Study NCT04635813 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Thyroidectomy
Study NCT04953624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Appetite rating scale CNAQ
Description: Chinese version of Appetite rating scale CNAQ
Study NCT01985763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Genistein combined with FOLFOX or FOLFOX-Avastin
Study NCT00683969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (CellCept)
Description: 1g bid for 36 weeks
Study NCT00683969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po bid for 36 weeks
Study NCT04073758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Comparing effects of remifentanil versus dexmedetomidine
Study NCT04073758 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexmedetomidine
Description: Comparing effects of remifentanil versus dexmedetomidine
Study NCT02629341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional yogurt powder
Description: Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10
Study NCT02629341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control yogurt powder
Description: Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
Study NCT02436759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVL-1201
Description: RVL-1201 Ophthalmic Solution 0.1%
Study NCT02436759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RVL-1201 Vehicle Placebo
Description: RVL-1201 Vehicle Placebo
Study NCT03812692 — intervention group
Intervention type: DEVICE
Intervention: MATRx plus
Description: The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
Study NCT03171454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Intrauterine Balloon therapy
Description: D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
Study NCT03171454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate Intrauterine Balloon therapy
Description: At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
Study NCT03849404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
Study NCT02109146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Transcatheter Arterial Chemoembolization
Description: Participants enrolled in the adjuvant TACE group received one to two cycles of TACE with an interval of 4\~6 weeks, and the first TACE was given within 1 week after randomization.
Study NCT02109146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Participants enrolled in the observation group were subjected to active surveillance without any adjuvant treatment.
Study NCT00708539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: 90 mg, vaginal, once daily
Study NCT00708539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
Study NCT01297205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Description: Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
Study NCT00295932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00295932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00295932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT03264287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 times per week therapeutic frequency
Description: Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
Study NCT03264287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 time per week therapeutic frequency
Description: Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
Study NCT00491387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
Study NCT01571258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.